S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients (2014/12/1)|
|Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen (2014/12/12)|
|Ipsen’s Somatuline® Depot® is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (2014/12/16)|
|Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (2014/12/16)|
|Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium (2015/1/13)|
|Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults (2015/1/26)|
|Ipsen: Sales in the Fourth Quarter and Full Year 2014 (2015/2/3)|
|Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults (2015/2/3)|
|Ipsen Enters into Option Agreement to Acquire Canbex Therapeutics (2015/2/24)|
Click above to view more mutual fund data and stats for ipn - Ipsen SA.